TRADENAME Novartis Pharmaceuticals Australia Pty Ltd
Product name
TRADENAME
Accepted date
Jun-2025
Active ingredients
remibrutinib
Proposed indication
Remibrutinib is for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite antihistamine treatment. CSU refers to hives that have no known cause, are frequent, and that last six weeks or more.
Application type
A (new medicine)
Publication date
Jun-2025